和黄医药中期亏损扩至4,970万美元
和黄医药(HCM.US)公布截至今年6月30日止六个月未经审核财务业绩。收入1.068亿美元(下同),按年增长4.5%。亏损4,970万元,按年扩阔9.47%。
和黄医药主席杜志强表示,公司上半年继续致力於中国建立由研发到生产及商业化和销售的高度一体化业务,并专注於肿瘤领域。索凡替尼和沃利替尼的新药上市申请目前正在中国国家药品监督管理局的审评过程中,现正通过新成立的专注於肿瘤的商业化团队紧密筹备多项潜在产品上市,并将覆盖中国大陆的所有省份。
公司目前拥有9个处於临床阶段的创新候选药物,此外还有5个创新药物正在新药临床试验申请阶段,期望在未来的12至18个月内会有多个创新肿瘤药物推向市场。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.